Clinical Trial: Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using GLP-1 RA Medications for Weight Loss

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07611552) titled 'Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using GLP-1 RA Medications for Weight Loss' on May 21.

Brief Summary: The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10g/day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving GLP-1 RA medications for weight loss.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Obesity & Overweight

Intervention: DIETARY_SUPPLEMENT: inulin (prebiotics)

The intervention dose is 10g/day. The intervention will last for 4 months....